Traws Pharma Reports Q3 2025 Financial Results

Tip Ranks
2025.11.13 12:29
portai
I'm PortAI, I can summarize articles.

Traws Pharma announced Q3 2025 financial results, highlighting cost reductions, intellectual property acquisitions, and a strategic shift towards antiviral programs. The company is advancing Phase 2 studies for COVID-19 and flu therapies. Despite a decrease in net loss, Spark rates TRAW stock as Underperform due to financial challenges. Recent positive trial data and new financing offer hope for future improvements. Traws Pharma focuses on developing therapies for respiratory viral diseases, targeting significant market opportunities.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

The latest update is out from Traws Pharma ( (TRAW) ).

On November 13, 2025, Traws Pharma announced its financial results for the quarter ending September 30, 2025, highlighting significant cost reductions and the acquisition of intellectual property assets. The company is advancing its Phase 2 studies for ratutrelvir, a potential COVID-19 therapy, and tivoxavir marboxil for bird flu and seasonal flu, both representing substantial market opportunities. The company also reported management updates and a decrease in net loss compared to the previous year, indicating a strategic shift towards antiviral programs and partnerships for legacy oncology assets.

The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.

Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to address critical threats from respiratory viral diseases. The company is working on antiviral programs, including treatments for COVID-19, bird flu, and seasonal flu, with a market focus on multi-billion dollar opportunities in the U.S.

Average Trading Volume: 179,566

Technical Sentiment Signal: Sell

Current Market Cap: $15.25M

Learn more about TRAW stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.